Le Lézard
Classified in: Health
Subject: PDT

Muno-Vax Takes a Lesson from the Fountain of Youth


FORT LAUDERDALE, Fla., Sept. 22, 2021 /PRNewswire/ -- Muno-Vax is an innovative health and wellness company committed to results. The brand uses quality ingredients, including its patented immuno-modulator to maximize the body's immune system. This, in turn, can translate to a longer, high-quality life.

Life expectancy in the U.S. dropped to 77.8 years in 2020. Of course, this average is dependent on a host of different factors. As always, women tended to live several years longer than men. In addition, race made a big difference in how old or young one might expect to live.

Of course, the biggest element that impacts everyone's life expectancy is health. If someone is in good health, it doesn't matter what their situation is. They can expect to live for a long time. At the same time, if they fall ill, it can shorten their lifespan, as well.

Muno-Vax is a company that is interested in getting the most out of health-related life expectancy. The U.S.-based company works with its manufacturing partner, Natstim, to create, market, and distribute health and wellness supplements. According to the brand, "The products were created to fill a great void in products that promote immune health to prevent respiratory illnesses, gingivitis, and men's prostate health."

Muno-Vax products use vitamins and minerals to enhance the body's health. But where the brand stands apart is its use of a potent immuno-modulator that it claims "no other products contain." Muno-Vax describes this hero ingredient as "certain lipopolysaccharides and immune-building antioxidants that present a harmless stimulant to the immune system." This external antigen or stimulus is designed to keep white blood cells at a certain level of "excitement" that improves the body's ability to fight off respiratory infections.

The ultimate goal of Muno-Vax's products is to maintain a very healthy immune system. This uses the body's own natural defenses to protect itself, which can have some very pleasant long-term effects. As the brand puts it, "Almost 75% of deaths in the elderly are caused by respiratory illnesses. We want to convey to the general public that one can have a very healthy immune system thus giving them a much higher quality of life and extending their life span."

About Muno-Vax: Muno-Vax is an American company that works in close association with its manufacturing partner, Bulgarian-based Natstim, Ltd. Together, the two brands represent 30 years of combined scientific research in relation to both preventing infections and bolstering the immune system. The company is most well known for its unique, patented ingredient, which it refers to as an immuno-modulator. This is used to stimulate the immune system and increase its effectiveness against foreign invaders.

Please direct inquiries to:
Brenna Anderson
(954) 774-6343
[email protected] 

SOURCE Muno-Vax


These press releases may also interest you

at 10:31
Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...

at 10:30
Vaccines Market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029 according to a new report by MarketsandMarketstm. Similarly, the vaccines...

at 10:25
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-007 will be presented at the American Society...

at 10:20
A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in Chicago, Illinois. The COVID-19 Monument of Honor, Remembrance, and Resilience...

at 10:20
Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy...

at 10:20
The two poster presentations will report -first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy armcombination data from the...



News published on and distributed by: